Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies
Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies have?
Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies published?
Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies has 2025 year in the ScholarIQ index.
What is the open-access status of Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies?
Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies has green oa status in the ScholarIQ index.
What is the DOI of Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies?
The DOI for Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies is on the source record.
What is the PMID of Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies?
The PMID for Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies is on the source record.
What is the OpenAlex record for Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies?
The OpenAlex for Health care resource utilization and costs of commercially insured US patients with atopic dermatitis switching from first-line to second-line systemic targeted therapies is on the source record.